Table 3 Adverse events (n = 23)
Placebo (n = 9) | Topiramate (n = 14) | Total (n = 23) | |
|---|---|---|---|
Sedative effects or psychomotor slowdowns | 0 | 4 (28.6%) | 4 (17.4%) |
Anxiety and tears | 1 (11%) | 0 | 1 (4.3%) |
Suicidal ideation | 1 (11%) | 0 | 1 (4.3%) |
Hospitalisation (suicidal attempt) | 1 (11%) | 0 | 1 (4.3%) |
Biological modifications in hepatic function | 3 (33.3%) | 4 (28.6%) | 7 (30.4%) |
Hyperammonaemia | 2 (22%) | 4 (28.6%) | 6 (26%) |
Skin rash | 1 (11%) | 0 | 1 (4.3%) |
Infectious episode | 0 | 2 (14.2%) | 2 (8.7%) |
